# Seagen, a wholly owned subsidiary of trials: 30 (2026)

ClinicalTrials.gov lists 30 trials with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor, 4 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Seagen, a wholly owned subsidiary of Pfizer: 30 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/seagen-a-wholly-owned-subsidiary-of-pfizer

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 12, 2024 | NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06549816) |
| June 20, 2024 | NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Terminated | Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other... | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06466187) |
| February 12, 2024 | NCT06254495 | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Terminated | Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06254495) |
| December 6, 2023 | NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | Active not recruiting | Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms... | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06157892) |
| November 14, 2023 | NCT06131840 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Recruiting | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma... | 914 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06131840) |
| November 7, 2023 | NCT06120504 | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Terminated | Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06120504) |
| August 25, 2023 | NCT06012435 | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 | Active not recruiting | Carcinoma, Non-Small-Cell Lung | 762 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06012435) |
| August 21, 2023 | NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | Active not recruiting | Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06003231) |
| August 9, 2023 | NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Terminated | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal... | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05983133) |
| June 22, 2023 | NCT05911295 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 | Active not recruiting | Urothelial Carcinoma | 412 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05911295) |
| June 15, 2023 | NCT05902494 | HER2 and LA/mUC: A Multi-country Chart Review Cohort Study | Seagen, a wholly owned subsidiary of Pfizer | Observational | Completed | Urothelial Carcinoma | 389 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05902494) |
| October 7, 2022 | NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Terminated | Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05571839) |
| February 24, 2022 | NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 | Active not recruiting | Colorectal Neoplasms | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05253651) |
| January 26, 2022 | NCT05208762 | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Recruiting | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma... | 714 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05208762) |
| January 18, 2022 | NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Terminated | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05194072) |
| November 24, 2021 | NCT05132582 | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 | Active not recruiting | HER2 Positive Breast Cancer | 654 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05132582) |
| May 10, 2021 | NCT04879329 | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | Recruiting | Urothelial Carcinoma | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04879329) |
| January 6, 2021 | NCT04697628 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 | Completed | Cervical Cancer | 502 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04697628) |
| October 30, 2020 | NCT04609566 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | Completed | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04609566) |
| October 8, 2020 | NCT04579380 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | Active not recruiting | Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell... | 217 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04579380) |
| September 29, 2020 | NCT04569032 | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | Completed | Peripheral T-cell Lymphoma | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04569032) |
| September 7, 2020 | NCT04539938 | A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | Completed | HER2 Positive Breast Cancer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04539938) |
| June 12, 2020 | NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | Active not recruiting | Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04430738) |
| May 27, 2020 | NCT04404283 | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 | Active not recruiting | Diffuse Large B-cell Lymphoma | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04404283) |
| May 15, 2020 | NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Recruiting | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal... | 1,006 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04389632) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 1 |
| Phase 2 | 9 |
| Phase 3 | 7 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Active not recruiting | 12 |
| Terminated | 7 |
| Completed | 6 |
| Recruiting | 4 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Colorectal Neoplasms | 9 |
| Squamous Cell Carcinoma of Head and Neck | 6 |
| Stomach Neoplasms | 5 |
| Ovarian Neoplasms | 5 |
| Breast Neoplasms | 4 |
| Uterine Cervical Neoplasms | 4 |
| Urinary Bladder Neoplasms | 4 |
| Adenocarcinoma Of Esophagus | 3 |
| Esophageal Squamous Cell Carcinoma | 3 |
| Lung Neoplasms | 3 |
| Triple Negative Breast Neoplasms | 3 |
| Carcinoma, Transitional Cell | 3 |
| Endometrial Neoplasms | 3 |
| Lymphoma, Large B-Cell, Diffuse | 3 |
| Lymphoma, T-Cell, Peripheral | 3 |
| Cholangiocarcinoma | 2 |
| Gallbladder Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
| Pancreatic Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Melanoma | 2 |
| Hodgkin Disease | 2 |
| Lymphoma, Large-Cell, Anaplastic | 2 |
| Mesothelioma | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Stock brokers in the United States](https://specstream.ai/data/businesses/stock-brokers/united-states)
- [Fertilizer stores in the United States](https://specstream.ai/data/businesses/fertilizer-stores/united-states)
- [Taco restaurants in the United States](https://specstream.ai/data/businesses/taco-restaurants/united-states)
- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
- [Textile manufacturers in the United States](https://specstream.ai/data/businesses/textile-manufacturers/united-states)
- [Furniture rental companies in the United States](https://specstream.ai/data/businesses/furniture-rental-companies/united-states)
